Torrent Pharmaceuticals Ltd

BSE: 500420 NSE: TORNTPHARM
Torrent Pharmaceuticals Ltd - pharma in Daskroi, Gujarat, India. FY 2026 financials and compliance.
CIN L24230GJ1972PLC002126 Incorporated 15 July 1972 ROC Ahmedabad HQ Daskroi, Gujarat, India
Active Listed - NSE: TORNTPHARM · BSE: 500420 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹13,980 Cr
▲ 21.4% YoY
Computed EBITDA · FY 2026
₹4,465 Cr
▲ 19.26% YoY
Net profit · FY 2026
₹2,138 Cr
▲ 11.88% YoY
Authorised capital
₹235 Cr
Registered with MCA
Paid-up capital
₹169.22 Cr
Issued & subscribed
Open charges
₹13,352 Cr
Satisfied ₹10,034 Cr
Company age
54 yrs
Est. 1972
Employees · EPFO
15,615
Latest available

About Torrent Pharmaceuticals Ltd

Data last updated: 14 July 2026

Torrent Pharmaceuticals Ltd is a public limited company based in Daskroi, Gujarat, India, a subsidiary of Torrent Investments Private Limited. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 15 July 1972, the company has been in operation for over 54 years.

Registered with ROC Ahmedabad under CIN L24230GJ1972PLC002126. Listed on BSE: 500420 and NSE: TORNTPHARM.

Capital: an authorised share capital of ₹235 Cr and a paid-up capital of ₹169.22 Cr. Formerly known as Torrent Laboratories Private Limited and Torrent Pharmaceuticals Pvt Ltd. It is led by directors including Samir Uttamlal Mehta and Nayantara Bali.

Last AGM: 28 July 2025. Financial statements filed for year ended 31 March 2025. Office: Daskroi, Gujarat.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹13,980 Cr, a growth of 21.4% compared to the previous year. The net worth stands at ₹17,585 Cr (up 131.66% YoY). Total assets are valued at ₹44,312 Cr (up 195.61% YoY).

The company has a workforce of approximately 15,615 employees as per the latest available data. It operates as a subsidiary of Torrent Investments Private Limited.

The company is associated with 2 brands - Tedibar, Torrent Pharma. As per MCA filings, the company has open charges of ₹13,352 Cr and satisfied charges of ₹10,034 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website torrentpharma.com.

Company Details of Torrent Pharmaceuticals Ltd
CIN L24230GJ1972PLC002126
Registration Number 002126
Incorporation Date 15 July 1972
ROC Ahmedabad
Listing Status Listed (BSE: 500420, NSE: TORNTPHARM)
Company Status Active
Date of Last AGM 28 July 2025
Date of Balance Sheet 31 March 2025
Parent Company Torrent Investments Private Limited
Compliance Status Active Compliant
Key People
Samir Uttamlal Mehta Managing Director Aman Samir Mehta Managing Director Nayantara Bali Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    torrentpharma.com
  • Social Media
  • Registered Address
    Avirat, Thaltej Shilaj Road Ahmedabad, Daskroi, Gujarat, India – 380059
  • Industry
    Pharma, Drug Formulation & Development
Company report
Torrent Pharmaceuticals Ltd - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Torrent Pharmaceuticals Ltd report

Financials, compliance, directors, charges, ownership and filings for Torrent Pharmaceuticals Ltd in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd has undergone 2 name changes throughout its history. The company was previously known as Torrent Laboratories Private Limited, and Torrent Pharmaceuticals Pvt Ltd. The current legal name is Torrent Pharmaceuticals Ltd, reflecting the company's evolution and rebranding over time.

Company Name Status
Torrent Pharmaceuticals Ltd Current
Torrent Laboratories Private Limited Previous
Torrent Pharmaceuticals Pvt Ltd Previous

Associated Brands with Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd operates two associated brands: Tedibar and Torrent Pharma. These brands represent Torrent Pharmaceuticals Ltd's diversified market presence and brand portfolio.

Brand Description Website
Tedibar
Offers gentle, moisturizing baby bathing bars and washes for sensitive skin care. tedibar.com
Torrent Pharma
Formulations, APIs, drug discovery, marketing, and sales services are provided. torrentpharma.com

Competitors & Alternatives of Torrent Pharmaceuticals Ltd

Brands and companies operating in the same space as Torrent Pharmaceuticals Ltd include Mother Sparsh Baby Care, The Unbottle, Tiny Mighty and 3 more.

Competitor Description Location Founded
Mother Sparsh Baby Care Mother Sparsh Baby Care Ayurvedic baby care products are manufactured and distributed. Ambala, India, India 2015
The Unbottle The Unbottle Multi-category Ayurvedic beauty care products are offered online. Kochi, India, India 2021
Tiny Mighty Tiny Mighty Online brand offering health and personal care products for children and babies Ahmedabad, India, India 2017
Herby Angel Herby Angel Online platform offering ayurvedic personal care products for babies and kids Noida, India, India 2022
Little Angel Little Angel Learning content for kids is delivered via an online platform. - 2015
Root and Soil Root and Soil Offers organic baby care products like oils, creams, and wellness items online. Coimbatore, India, India 2019

Business Activity of Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Torrent Pharmaceuticals Ltd

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd is audited by BSR & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
BSR & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd is currently managed by 7 directors, with 23 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Samir Uttamlal Mehta
Also directs: Radiant Urja Llp, Abhivyakti Enterprise Llp, Akalpya Enterprise Llp and 4 more
Managing Director 01 Aug 2010 15 Years 11 Months Current
Nayantara Bali
Also directs: Marico Limited
Director 07 Mar 2019 7 Years 4 Months Current
Manish Mahendra Choksi
Also directs: Asian Paints Limited, Vedant Fashions Limited, Birlasoft Limited and 5 more
Director 29 Jul 2022 3 Years 11 Months Current
Ameera Sushil Shah
Also directs: Metz Advisory Llp, G&L Advisory Llp, Metropolis Healthcare Limited and 4 more
Director 02 Aug 2018 7 Years 11 Months Current
Aman Samir Mehta
Also directs: Radiant Urja Llp, Torrent Investments Limited, Torrent Gujarat Titans Private Limited and 2 more
Managing Director 31 Jul 2025 0 Years 11 Months Current
Jinal Sudhirbhai Mehta
Also directs: Radiant Urja Llp, Torrent Power Limited, Torrent Investments Limited and 4 more
Director 24 May 2024 2 Years 2 Months Current
Showing 6 of 7 current directors. View all directors

Financials of Torrent Pharmaceuticals Ltd FY 2026 filings available

Torrent Pharmaceuticals Ltd reported revenue of ₹13,980 Cr (up 21.4% YoY) for FY 2026.

Revenue · FY 2026
₹13,980 Cr ▲ 21.4%
Profit · FY 2026
₹2,138 Cr ▲ 11.88%
Computed EBITDA · FY 2026
₹4,465 Cr ▲ 19.26%
Revenue₹ Cr · Consolidated05,00010,00015,000FY 2020: ₹7,939 Cr7,939FY 2020FY 2021: ₹8,005 Cr · +0.8% YoY8,005+0.8%FY 2021FY 2022: ₹8,508 Cr · +6.3% YoY8,508+6.3%FY 2022FY 2023: ₹9,620 Cr · +13.1% YoY9,620+13.1%FY 2023FY 2024: ₹10,728 Cr · +11.5% YoY10,728+11.5%FY 2024FY 2025: ₹11,516 Cr · +7.3% YoY11,516+7.3%FY 2025FY 2026: ₹13,980 Cr · +21.4% YoY13,980+21.4%FY 2026
Net Profit₹ Cr · Consolidated01,0002,0003,000FY 2020: ₹1,025 Cr1,025FY 2020FY 2021: ₹1,252 Cr · +22.1% YoY1,252+22.1%FY 2021FY 2022: ₹777 Cr · -37.9% YoY777-37.9%FY 2022FY 2023: ₹1,245 Cr · +60.2% YoY1,245+60.2%FY 2023FY 2024: ₹1,656 Cr · +33% YoY1,656+33%FY 2024FY 2025: ₹1,911 Cr · +15.4% YoY1,911+15.4%FY 2025FY 2026: ₹2,138 Cr · +11.9% YoY2,138+11.9%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year02,0004,0006,000Q1'25: ₹2,859 Cr · +10.3% YoY2,859+10.3%Q1'25Q2'25: ₹2,889 Cr · +8.6% YoY2,889+8.6%Q2'25Q3'25: ₹2,809 Cr · +2.8% YoY2,809+2.8%Q3'25Q4'25: ₹2,959 Cr · +7.8% YoY2,959+7.8%Q4'25Q1'26: ₹3,178 Cr · +11.2% YoY3,178+11.2%Q1'26Q2'26: ₹3,302 Cr · +14.3% YoY3,302+14.3%Q2'26Q3'26: ₹3,303 Cr · +17.6% YoY3,303+17.6%Q3'26Q4'26: ₹4,197 Cr · +41.8% YoY4,197+41.8%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹13,980 Cr ₹11,516 Cr ₹10,728 Cr ₹9,620 Cr ₹8,508 Cr ₹8,005 Cr ₹7,939 Cr
Other Income -₹94 Cr ₹23 Cr ₹58 Cr ₹45 Cr ₹197 Cr ₹57 Cr ₹122 Cr
Total Income ₹13,886 Cr ₹11,539 Cr ₹10,786 Cr ₹9,665 Cr ₹8,705 Cr ₹8,062 Cr ₹8,061 Cr
Cost of Materials Consumed ₹1,758 Cr ₹1,520 Cr ₹1,657 Cr ₹1,480 Cr ₹1,538 Cr ₹1,421 Cr ₹1,377 Cr
Purchases of Stock-in-Trade ₹1,619 Cr ₹1,531 Cr ₹1,184 Cr ₹1,089 Cr ₹831 Cr ₹1,005 Cr ₹923 Cr
Changes in Inventories ₹11 Cr -₹275 Cr -₹155 Cr ₹166 Cr ₹74 Cr -₹279 Cr -₹133 Cr
Employee Benefit Expense ₹2,671 Cr ₹2,203 Cr ₹1,984 Cr ₹1,678 Cr ₹1,526 Cr ₹1,440 Cr ₹1,429 Cr
Finance Costs ₹385 Cr ₹252 Cr ₹354 Cr ₹333 Cr ₹255 Cr ₹358 Cr ₹451 Cr
Depreciation & Amortisation ₹1,119 Cr ₹795 Cr ₹808 Cr ₹707 Cr ₹662 Cr ₹658 Cr ₹654 Cr
Other Expenses ₹3,362 Cr ₹2,816 Cr ₹2,690 Cr ₹2,365 Cr ₹2,108 Cr ₹1,933 Cr ₹2,173 Cr
Total Expenses ₹10,925 Cr ₹8,842 Cr ₹8,522 Cr ₹7,818 Cr ₹6,994 Cr ₹6,536 Cr ₹6,874 Cr
Profit Before Exceptional Items & Tax ₹2,961 Cr ₹2,697 Cr ₹2,264 Cr ₹1,847 Cr ₹1,711 Cr ₹1,526 Cr ₹1,187 Cr
Exceptional Items -₹89 Cr -₹24 Cr ₹88 Cr ₹0 -₹485 Cr ₹0 ₹0
Profit Before Tax ₹2,872 Cr ₹2,673 Cr ₹2,352 Cr ₹1,847 Cr ₹1,226 Cr ₹1,526 Cr ₹1,187 Cr
Total Tax Expense ₹734 Cr ₹762 Cr ₹696 Cr ₹602 Cr ₹449 Cr ₹274 Cr ₹162 Cr
Net Profit ₹2,138 Cr ₹1,911 Cr ₹1,656 Cr ₹1,245 Cr ₹777 Cr ₹1,252 Cr ₹1,025 Cr
  attributable to Owners ₹2,163 Cr ₹1,911 Cr ₹1,656 Cr ₹1,245 Cr ₹777 Cr ₹1,252 Cr -
  attributable to NCI -₹25 Cr ₹0 ₹0 ₹0 ₹0 ₹0 -
Other Comprehensive Income -₹180 Cr -₹93 Cr ₹17 Cr -₹137 Cr ₹12 Cr ₹100 Cr -₹192 Cr
Total Comprehensive Income ₹1,958 Cr ₹1,818 Cr ₹1,673 Cr ₹1,108 Cr ₹789 Cr ₹1,352 Cr ₹833 Cr
EBITDA (computed) ₹4,465 Cr ₹3,744 Cr ₹3,426 Cr ₹2,887 Cr ₹2,628 Cr ₹2,542 Cr ₹2,292 Cr
Basic EPS ₹63.92 ₹56.47 ₹48.94 ₹36.79 ₹45.93 ₹73.98 ₹60.55
Diluted EPS ₹63.92 ₹56.47 ₹48.94 ₹36.79 ₹0.00 ₹73.98 ₹60.55
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹44,312 Cr ₹14,990 Cr ₹15,061 Cr ₹15,012 Cr
Non-current Assets ₹34,919 Cr ₹9,367 Cr ₹9,450 Cr ₹9,683 Cr
Current Assets ₹9,392 Cr ₹5,623 Cr ₹5,611 Cr ₹5,314 Cr
Property, Plant & Equipment ₹4,909 Cr ₹3,455 Cr ₹3,297 Cr ₹2,772 Cr
Inventories ₹3,138 Cr ₹2,541 Cr ₹2,279 Cr ₹2,230 Cr
Trade Receivables ₹3,031 Cr ₹1,867 Cr ₹1,844 Cr ₹1,944 Cr
Cash & Equivalents ₹1,117 Cr ₹573 Cr ₹835 Cr ₹508 Cr
Equity (Net Worth) ₹17,585 Cr ₹7,591 Cr ₹6,856 Cr ₹6,198 Cr
Equity Share Capital ₹169 Cr ₹169 Cr ₹169 Cr ₹169 Cr
Borrowings (Non-current) ₹11,651 Cr ₹1,192 Cr ₹1,604 Cr ₹2,496 Cr
Borrowings (Current) ₹3,147 Cr ₹1,834 Cr ₹2,334 Cr ₹2,801 Cr
Total Debt (computed) ₹14,798 Cr ₹3,026 Cr ₹3,938 Cr ₹5,297 Cr
Current Liabilities ₹8,343 Cr ₹4,717 Cr ₹5,426 Cr ₹5,447 Cr
Total Liabilities ₹26,727 Cr ₹7,399 Cr ₹8,205 Cr ₹8,814 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹3,023 Cr ₹2,585 Cr ₹3,266 Cr ₹2,368 Cr ₹1,803 Cr
Investing Cash Flow -₹12,713 Cr -₹540 Cr -₹168 Cr -₹2,356 Cr -₹198 Cr
Financing Cash Flow ₹10,151 Cr -₹2,298 Cr -₹2,779 Cr ₹77 Cr -₹1,781 Cr
Capital Expenditure ₹677 Cr ₹611 Cr ₹433 Cr ₹574 Cr ₹203 Cr
Free Cash Flow (computed) ₹2,346 Cr ₹1,974 Cr ₹2,833 Cr ₹1,794 Cr ₹1,600 Cr
Dividends Paid ₹1,289 Cr ₹1,083 Cr ₹1,015 Cr ₹863 Cr ₹677 Cr
Net Change in Cash ₹544 Cr -₹262 Cr ₹327 Cr ₹110 Cr -₹175 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹4,197 Cr ₹3,303 Cr ₹3,302 Cr ₹3,178 Cr ₹2,959 Cr ₹2,809 Cr ₹2,889 Cr ₹2,859 Cr ₹2,745 Cr ₹2,732 Cr ₹2,660 Cr ₹2,591 Cr
Other Income -₹17 Cr -₹13 Cr -₹27 Cr -₹37 Cr -₹18 Cr ₹33 Cr -₹16 Cr ₹24 Cr ₹31 Cr -₹33 Cr ₹26 Cr ₹34 Cr
Total Income ₹4,180 Cr ₹3,290 Cr ₹3,275 Cr ₹3,141 Cr ₹2,941 Cr ₹2,842 Cr ₹2,873 Cr ₹2,883 Cr ₹2,776 Cr ₹2,699 Cr ₹2,686 Cr ₹2,625 Cr
Cost of Materials Consumed ₹566 Cr ₹414 Cr ₹382 Cr ₹396 Cr ₹402 Cr ₹370 Cr ₹337 Cr ₹411 Cr ₹410 Cr ₹379 Cr ₹433 Cr ₹435 Cr
Purchases of Stock-in-Trade ₹477 Cr ₹422 Cr ₹382 Cr ₹338 Cr ₹416 Cr ₹420 Cr ₹382 Cr ₹313 Cr ₹315 Cr ₹327 Cr ₹292 Cr ₹250 Cr
Changes in Inventories -₹28 Cr -₹37 Cr ₹36 Cr ₹40 Cr -₹87 Cr -₹117 Cr -₹41 Cr -₹30 Cr -₹46 Cr -₹9 Cr -₹65 Cr -₹35 Cr
Employee Benefit Expense ₹788 Cr ₹651 Cr ₹627 Cr ₹605 Cr ₹561 Cr ₹549 Cr ₹543 Cr ₹550 Cr ₹486 Cr ₹496 Cr ₹503 Cr ₹499 Cr
Finance Costs ₹236 Cr ₹45 Cr ₹48 Cr ₹56 Cr ₹56 Cr ₹57 Cr ₹64 Cr ₹75 Cr ₹80 Cr ₹80 Cr ₹91 Cr ₹103 Cr
Depreciation & Amortisation ₹508 Cr ₹206 Cr ₹204 Cr ₹201 Cr ₹201 Cr ₹199 Cr ₹198 Cr ₹197 Cr ₹203 Cr ₹213 Cr ₹201 Cr ₹191 Cr
Other Expenses ₹1,038 Cr ₹765 Cr ₹792 Cr ₹767 Cr ₹703 Cr ₹673 Cr ₹729 Cr ₹711 Cr ₹697 Cr ₹670 Cr ₹672 Cr ₹651 Cr
Total Expenses ₹3,585 Cr ₹2,466 Cr ₹2,471 Cr ₹2,403 Cr ₹2,252 Cr ₹2,151 Cr ₹2,212 Cr ₹2,227 Cr ₹2,145 Cr ₹2,156 Cr ₹2,127 Cr ₹2,094 Cr
Profit Before Exceptional Items & Tax ₹595 Cr ₹824 Cr ₹804 Cr ₹738 Cr ₹689 Cr ₹691 Cr ₹661 Cr ₹656 Cr ₹631 Cr ₹543 Cr ₹559 Cr ₹531 Cr
Exceptional Items -₹66 Cr -₹10 Cr -₹13 Cr ₹0 -₹24 Cr ₹0 ₹0 ₹0 ₹0 ₹88 Cr ₹0 ₹0
Profit Before Tax ₹529 Cr ₹814 Cr ₹791 Cr ₹738 Cr ₹665 Cr ₹691 Cr ₹661 Cr ₹656 Cr ₹631 Cr ₹631 Cr ₹559 Cr ₹531 Cr
Total Tax Expense ₹165 Cr ₹179 Cr ₹200 Cr ₹190 Cr ₹167 Cr ₹188 Cr ₹208 Cr ₹199 Cr ₹182 Cr ₹188 Cr ₹173 Cr ₹153 Cr
Net Profit ₹364 Cr ₹635 Cr ₹591 Cr ₹548 Cr ₹498 Cr ₹503 Cr ₹453 Cr ₹457 Cr ₹449 Cr ₹443 Cr ₹386 Cr ₹378 Cr
  attributable to Owners ₹389 Cr ₹635 Cr ₹591 Cr ₹548 Cr ₹498 Cr - - ₹457 Cr ₹449 Cr ₹442 Cr ₹363 Cr ₹378 Cr
  attributable to NCI -₹25 Cr ₹0 ₹0 ₹0 ₹0 - - ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income -₹86 Cr -₹16 Cr -₹76 Cr -₹2 Cr ₹36 Cr -₹70 Cr -₹25 Cr -₹34 Cr ₹1 Cr -₹1 Cr -₹23 Cr ₹40 Cr
Total Comprehensive Income ₹278 Cr ₹619 Cr ₹515 Cr ₹546 Cr ₹534 Cr ₹433 Cr ₹428 Cr ₹423 Cr ₹450 Cr ₹442 Cr ₹363 Cr ₹418 Cr
EBITDA (computed) ₹1,339 Cr ₹1,075 Cr ₹1,056 Cr ₹995 Cr ₹946 Cr ₹947 Cr ₹923 Cr ₹928 Cr ₹914 Cr ₹836 Cr ₹851 Cr ₹825 Cr
Basic EPS ₹11.51 ₹18.77 ₹17.45 ₹16.19 ₹14.71 ₹14.88 ₹13.37 ₹13.51 ₹13.27 ₹13.10 ₹11.39 ₹11.18
Diluted EPS ₹11.51 ₹18.77 ₹17.45 ₹16.19 ₹14.71 ₹14.88 ₹13.37 ₹13.51 ₹13.27 ₹13.10 ₹11.39 ₹11.18
Latest 12 quarters shown of 24 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹10,712 Cr ₹9,682 Cr ₹8,533 Cr ₹7,695 Cr ₹6,742 Cr ₹6,451 Cr ₹6,168 Cr
Other Income ₹18 Cr ₹32 Cr ₹91 Cr ₹82 Cr ₹204 Cr ₹118 Cr ₹237 Cr
Total Income ₹10,730 Cr ₹9,714 Cr ₹8,624 Cr ₹7,777 Cr ₹6,946 Cr ₹6,569 Cr ₹6,405 Cr
Cost of Materials Consumed ₹1,567 Cr ₹1,518 Cr ₹1,652 Cr ₹1,477 Cr ₹1,529 Cr ₹1,421 Cr ₹1,353 Cr
Purchases of Stock-in-Trade ₹767 Cr ₹732 Cr ₹548 Cr ₹534 Cr ₹397 Cr ₹399 Cr ₹341 Cr
Changes in Inventories -₹22 Cr -₹9 Cr -₹69 Cr ₹128 Cr -₹18 Cr -₹150 Cr -₹57 Cr
Employee Benefit Expense ₹1,879 Cr ₹1,636 Cr ₹1,451 Cr ₹1,251 Cr ₹1,098 Cr ₹1,097 Cr ₹1,062 Cr
Finance Costs ₹341 Cr ₹213 Cr ₹303 Cr ₹298 Cr ₹236 Cr ₹339 Cr ₹430 Cr
Depreciation & Amortisation ₹764 Cr ₹760 Cr ₹761 Cr ₹672 Cr ₹602 Cr ₹610 Cr ₹607 Cr
Other Expenses ₹2,467 Cr ₹2,230 Cr ₹2,061 Cr ₹1,840 Cr ₹1,636 Cr ₹1,487 Cr ₹1,552 Cr
Total Expenses ₹7,763 Cr ₹7,080 Cr ₹6,707 Cr ₹6,200 Cr ₹5,480 Cr ₹5,203 Cr ₹5,288 Cr
Profit Before Exceptional Items & Tax ₹2,967 Cr ₹2,634 Cr ₹1,917 Cr ₹1,577 Cr ₹1,466 Cr ₹1,366 Cr ₹1,117 Cr
Exceptional Items -₹70 Cr -₹24 Cr ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹2,897 Cr ₹2,610 Cr ₹1,917 Cr ₹1,577 Cr ₹1,466 Cr ₹1,366 Cr ₹1,117 Cr
Total Tax Expense ₹705 Cr ₹722 Cr ₹560 Cr ₹525 Cr ₹475 Cr ₹228 Cr ₹178 Cr
Net Profit ₹2,192 Cr ₹1,888 Cr ₹1,357 Cr ₹1,052 Cr ₹991 Cr ₹1,138 Cr ₹939 Cr
Other Comprehensive Income -₹147 Cr -₹41 Cr ₹31 Cr -₹78 Cr ₹1 Cr ₹110 Cr -₹115 Cr
Total Comprehensive Income ₹2,045 Cr ₹1,847 Cr ₹1,388 Cr ₹974 Cr ₹992 Cr ₹1,248 Cr ₹824 Cr
EBITDA (computed) ₹4,072 Cr ₹3,607 Cr ₹2,981 Cr ₹2,547 Cr ₹2,304 Cr ₹2,315 Cr ₹2,154 Cr
Basic EPS ₹64.75 ₹55.79 ₹40.10 ₹31.07 ₹58.59 ₹67.24 ₹55.46
Diluted EPS ₹64.75 ₹55.79 ₹40.10 ₹31.07 ₹58.59 ₹67.24 ₹55.46
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹25,814 Cr ₹12,842 Cr ₹12,377 Cr ₹12,872 Cr
Non-current Assets ₹20,922 Cr ₹8,493 Cr ₹8,635 Cr ₹8,946 Cr
Current Assets ₹4,891 Cr ₹4,349 Cr ₹3,742 Cr ₹3,926 Cr
Property, Plant & Equipment ₹3,336 Cr ₹3,132 Cr ₹3,205 Cr ₹2,688 Cr
Inventories ₹1,526 Cr ₹1,561 Cr ₹1,566 Cr ₹1,602 Cr
Trade Receivables ₹2,641 Cr ₹2,171 Cr ₹1,572 Cr ₹1,729 Cr
Cash & Equivalents ₹71 Cr ₹105 Cr ₹105 Cr ₹85 Cr
Equity (Net Worth) ₹8,452 Cr ₹7,592 Cr ₹6,829 Cr ₹6,456 Cr
Equity Share Capital ₹169 Cr ₹169 Cr ₹169 Cr ₹169 Cr
Borrowings (Non-current) ₹11,462 Cr ₹1,021 Cr ₹1,604 Cr ₹2,332 Cr
Borrowings (Current) ₹2,702 Cr ₹1,526 Cr ₹1,729 Cr ₹2,234 Cr
Total Debt (computed) ₹14,164 Cr ₹2,547 Cr ₹3,333 Cr ₹4,566 Cr
Current Liabilities ₹4,590 Cr ₹2,980 Cr ₹2,989 Cr ₹3,409 Cr
Total Liabilities ₹17,362 Cr ₹5,250 Cr ₹5,548 Cr ₹6,416 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹2,731 Cr ₹2,574 Cr ₹2,893 Cr ₹2,266 Cr ₹2,140 Cr
Investing Cash Flow -₹12,991 Cr -₹470 Cr -₹296 Cr -₹2,327 Cr -₹160 Cr
Financing Cash Flow ₹10,226 Cr -₹2,104 Cr -₹2,577 Cr ₹81 Cr -₹1,977 Cr
Capital Expenditure ₹510 Cr ₹446 Cr ₹344 Cr ₹571 Cr ₹108 Cr
Free Cash Flow (computed) ₹2,221 Cr ₹2,128 Cr ₹2,549 Cr ₹1,695 Cr ₹2,032 Cr
Dividends Paid ₹1,185 Cr ₹1,083 Cr ₹1,015 Cr ₹863 Cr ₹677 Cr
Net Change in Cash -₹34 Cr ₹0 ₹20 Cr ₹20 Cr ₹3 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹2,735 Cr ₹2,599 Cr ₹2,762 Cr ₹2,616 Cr ₹2,433 Cr ₹2,377 Cr ₹2,434 Cr ₹2,438 Cr ₹2,143 Cr ₹2,123 Cr ₹2,146 Cr ₹2,121 Cr
Other Income ₹58 Cr -₹8 Cr -₹27 Cr -₹5 Cr ₹15 Cr ₹3 Cr -₹7 Cr ₹21 Cr ₹76 Cr -₹11 Cr ₹15 Cr ₹11 Cr
Total Income ₹2,793 Cr ₹2,591 Cr ₹2,735 Cr ₹2,611 Cr ₹2,448 Cr ₹2,380 Cr ₹2,427 Cr ₹2,459 Cr ₹2,219 Cr ₹2,112 Cr ₹2,161 Cr ₹2,132 Cr
Cost of Materials Consumed ₹380 Cr ₹411 Cr ₹382 Cr ₹394 Cr ₹402 Cr ₹369 Cr ₹337 Cr ₹410 Cr ₹409 Cr ₹376 Cr ₹433 Cr ₹434 Cr
Purchases of Stock-in-Trade ₹210 Cr ₹198 Cr ₹186 Cr ₹173 Cr ₹205 Cr ₹211 Cr ₹175 Cr ₹141 Cr ₹168 Cr ₹129 Cr ₹138 Cr ₹113 Cr
Changes in Inventories -₹19 Cr -₹73 Cr ₹53 Cr ₹17 Cr -₹28 Cr -₹36 Cr ₹23 Cr ₹32 Cr -₹39 Cr ₹56 Cr -₹46 Cr -₹40 Cr
Employee Benefit Expense ₹487 Cr ₹479 Cr ₹460 Cr ₹453 Cr ₹416 Cr ₹407 Cr ₹407 Cr ₹406 Cr ₹353 Cr ₹363 Cr ₹366 Cr ₹369 Cr
Finance Costs ₹225 Cr ₹34 Cr ₹37 Cr ₹45 Cr ₹47 Cr ₹48 Cr ₹54 Cr ₹64 Cr ₹67 Cr ₹69 Cr ₹77 Cr ₹90 Cr
Depreciation & Amortisation ₹197 Cr ₹191 Cr ₹189 Cr ₹187 Cr ₹190 Cr ₹191 Cr ₹190 Cr ₹189 Cr ₹195 Cr ₹191 Cr ₹192 Cr ₹183 Cr
Other Expenses ₹674 Cr ₹584 Cr ₹609 Cr ₹600 Cr ₹570 Cr ₹539 Cr ₹571 Cr ₹550 Cr ₹536 Cr ₹498 Cr ₹519 Cr ₹508 Cr
Total Expenses ₹2,154 Cr ₹1,824 Cr ₹1,916 Cr ₹1,869 Cr ₹1,802 Cr ₹1,729 Cr ₹1,757 Cr ₹1,792 Cr ₹1,689 Cr ₹1,682 Cr ₹1,679 Cr ₹1,657 Cr
Profit Before Exceptional Items & Tax ₹639 Cr ₹767 Cr ₹819 Cr ₹742 Cr ₹646 Cr ₹651 Cr ₹670 Cr ₹667 Cr ₹530 Cr ₹430 Cr ₹482 Cr ₹475 Cr
Exceptional Items -₹47 Cr -₹10 Cr -₹13 Cr ₹0 -₹24 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹592 Cr ₹757 Cr ₹806 Cr ₹742 Cr ₹622 Cr ₹651 Cr ₹670 Cr ₹667 Cr ₹530 Cr ₹430 Cr ₹482 Cr ₹475 Cr
Total Tax Expense ₹125 Cr ₹180 Cr ₹209 Cr ₹191 Cr ₹148 Cr ₹166 Cr ₹210 Cr ₹198 Cr ₹120 Cr ₹133 Cr ₹155 Cr ₹152 Cr
Net Profit ₹467 Cr ₹577 Cr ₹597 Cr ₹551 Cr ₹474 Cr ₹485 Cr ₹460 Cr ₹469 Cr ₹410 Cr ₹297 Cr ₹327 Cr ₹323 Cr
Other Comprehensive Income -₹60 Cr -₹5 Cr -₹55 Cr -₹27 Cr -₹5 Cr -₹7 Cr -₹29 Cr ₹0 ₹14 Cr -₹13 Cr -₹3 Cr ₹33 Cr
Total Comprehensive Income ₹407 Cr ₹572 Cr ₹542 Cr ₹524 Cr ₹469 Cr ₹478 Cr ₹431 Cr ₹469 Cr ₹424 Cr ₹284 Cr ₹324 Cr ₹356 Cr
EBITDA (computed) ₹1,061 Cr ₹992 Cr ₹1,045 Cr ₹974 Cr ₹883 Cr ₹890 Cr ₹914 Cr ₹920 Cr ₹792 Cr ₹690 Cr ₹751 Cr ₹748 Cr
Basic EPS ₹13.80 ₹17.04 ₹17.64 ₹16.28 ₹14.00 ₹14.33 ₹13.60 ₹13.86 ₹12.12 ₹8.78 ₹9.65 ₹9.55
Diluted EPS ₹13.80 ₹17.04 ₹17.64 ₹16.28 ₹14.00 ₹14.33 ₹13.60 ₹13.86 ₹12.12 ₹8.78 ₹9.65 ₹9.55
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Torrent Pharmaceuticals Ltd. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Torrent Pharmaceuticals Ltd

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 68.31%, foreign institutional investors hold 16.18%, domestic institutional investors hold 9.06%, retail and other public shareholders hold 6.45% of Torrent Pharmaceuticals Ltd. The company had 83,811 shareholders on record.

Promoters: 68.31%DII (Domestic Institutional): 9.06%FII (Foreign Institutional): 16.18%Retail & Others: 6.45%
Mar 2026
QUARTER
68.31% Promoters
9.06% DII (Domestic Institutional)
16.18% FII (Foreign Institutional)
6.45% Retail & Others
Promoter holding - history
Now 68.31% · Mar 2026High 71.25% · Dec 2015Low 68.31% · Dec 2024
67%68.5%70%71.5%73%Dec 2015Jun 2018Sep 2020Dec 2022Jun 2025Dec 2015: 71.25%Mar 2016: 71.25%Jun 2016: 71.25%Sep 2016: 71.25%Dec 2016: 71.25%Mar 2017: 71.25%Jun 2017: 71.25%Sep 2017: 71.25%Dec 2017: 71.25%Mar 2018: 71.25%Jun 2018: 71.25%Sep 2018: 71.25%Dec 2018: 71.25%Mar 2019: 71.25%Jun 2019: 71.25%Sep 2019: 71.25%Dec 2019: 71.25%Mar 2020: 71.25%Apr 2020: 71.25%Jun 2020: 71.25%Sep 2020: 71.25%Dec 2020: 71.25%Mar 2021: 71.25%Jun 2021: 71.25%Sep 2021: 71.25%Dec 2021: 71.25%Mar 2022: 71.25%Jun 2022: 71.25%Jul 2022: 71.25%Sep 2022: 71.25%Dec 2022: 71.25%Mar 2023: 71.25%Jun 2023: 71.25%Sep 2023: 71.25%Dec 2023: 71.25%Mar 2024: 71.25%Jun 2024: 71.25%Sep 2024: 71.25%Dec 2024: 68.31%Mar 2025: 68.31%Jun 2025: 68.31%Sep 2025: 68.31%Dec 2025: 68.31%Mar 2026: 68.31%71.25%68.31%68.31%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters68.31%68.31%68.31%68.31%68.31%68.31%
Public31.69%31.69%31.69%31.69%31.69%31.69%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters68.31%68.31%71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%
Public31.69%31.69%28.75%28.75%28.75%28.75%28.75%28.75%28.75%28.75%28.75%
Promoter change (YoY, %pts)+0.00-2.94+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00-

Board & Governance of Torrent Pharmaceuticals Ltd

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Torrent Pharmaceuticals Ltd has 7 directors - 4 independent and 2 executive. The board is chaired by Samir Uttamlal Mehta.

DirectorPositionOn board sinceListed boards
Samir Uttamlal Mehta Executive Director · CEO-MD · Chairperson 1986-08-20 2
Ameera Sushil Shah Non-Executive - Independent Director 2018-08-02 2
Nayantara Bali Non-Executive - Independent Director 2019-03-07 2
Manish Mahendra Choksi Non-Executive - Independent Director 2022-07-29 4
Aman Mehta Executive Director · MD 2022-08-01 2
Nikhil Nirvan Khattau Non-Executive - Independent Director 2023-10-01 3
Jinal Sudhirbhai Mehta Non-Executive - Non Independent Director 2024-05-24 2
Board Committees
CommitteeMembers
Audit Committee Nikhil Nirvan Khattau (Chairperson), Ameera Sushil Shah, Nayantara Bali, Manish Mahendra Choksi
Nomination and remuneration committee Manish Mahendra Choksi (Chairperson), Nayantara Bali, Ameera Sushil Shah
Stakeholders Relationship Committee Ameera Sushil Shah (Chairperson), Aman Mehta, Nikhil Nirvan Khattau
Risk Management Committee Nikhil Nirvan Khattau (Chairperson), Nayantara Bali, Sudhir Menon
Corporate Social Responsibility Committee Nayantara Bali (Chairperson), Manish Mahendra Choksi, Nikhil Nirvan Khattau

Group Structure of Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd has 1 associated company. This group structure data is as of FY 2024. The corporate group structure reflects Torrent Pharmaceuticals Ltd's business expansion strategy and organizational complexity.

1
Associated companies

Charges & Borrowings of Torrent Pharmaceuticals Ltd

Open charges
₹13,352 Cr
Satisfied charges
₹10,034 Cr
Breakdown by lending institutions
Idbi Trusteeship Services Limited₹11,390.00 Cr
Hdfc Bank Limited₹716.88 Cr
Others₹550.00 Cr
The Hongkong and Shanghai Banking Corporation Limited₹350.00 Cr
Axis Bank Limited₹300.00 Cr
Others₹44.80 Cr
Latest charge details
DateLenderAmountStatus
08 Apr 2026 Hdfc Bank Limited ₹266.88 Cr Open
08 Apr 2026 The Hongkong and Shanghai Banking Corporation Limited ₹300 Cr Open
12 Jan 2026 Idbi Trusteeship Services Limited ₹10,990 Cr Open
07 Feb 2023 Idbi Trusteeship Services Limited ₹400 Cr Open
02 Apr 2022 Hdfc Bank Limited ₹450 Cr Open

Total charge records: 65 View all charges

Employees and EPFO Compliance at Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd has a workforce of 15,615 employees as of Mar 10, 2025.

Employee count
15,615
Active EPFO establishments
8
Employee growth
6.46%
Premium access

Employee and EPFO history for Torrent Pharmaceuticals Ltd

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Torrent Pharmaceuticals Ltd

Premium access

GST registrations and filing compliance for Torrent Pharmaceuticals Ltd

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Torrent Pharmaceuticals Ltd

Premium access

Credit ratings, litigation, and regulatory alerts for Torrent Pharmaceuticals Ltd

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Torrent Pharmaceuticals Ltd

Premium access

MSME payment history for Torrent Pharmaceuticals Ltd

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Torrent Pharmaceuticals Ltd

Premium access

Corporate group structure for Torrent Pharmaceuticals Ltd

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Torrent Pharmaceuticals Ltd

Premium access

MCA filings and documents for Torrent Pharmaceuticals Ltd

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Torrent Pharmaceuticals Ltd

Charges
11 Jun 2026
A charge registered on 05 Apr 2013 via Charge ID 10421600 with Bnp Paribas was fully satisfied on 11 Jun 2026.
Charges
08 Apr 2026
A charge with Hdfc Bank Limited amounted to Rs. 266.88 Cr with Charge ID 101282150 was registered on 08 Apr 2026.
Charges
08 Apr 2026
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 300.00 Cr with Charge ID 101283754 was registered on 08 Apr 2026.
Charges
08 Apr 2026
A charge with Idbi Trusteeship Services Limited of Rs. 400.00 Cr registered on 07 Feb 2023 with Charge ID 100688815 was modified on 08 Apr 2026.
Charges
05 Feb 2026
A charge registered on 12 Oct 2018 via Charge ID 100212700 with Idbi Trusteeship Services Limited was fully satisfied on 05 Feb 2026.
Charges
12 Jan 2026
A charge with Idbi Trusteeship Services Limited amounted to Rs. 10,990.00 Cr with Charge ID 101230130 was registered on 12 Jan 2026.

Recent News on Torrent Pharmaceuticals Ltd

Frequently Asked Questions about Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd is an active public limited company in the pharma sector based in Daskroi, Gujarat, India. It was incorporated on 15 July 1972 (54+ years old) and is registered under CIN L24230GJ1972PLC002126. Listed on BSE: 500420 and NSE: TORNTPHARM. The company has 15,615 employees.

Torrent Pharmaceuticals Ltd reported revenue of ₹13,980 Cr for FY 2026 (up 21.4% YoY) based on consolidated NSE filings.

The current directors of Torrent Pharmaceuticals Ltd are:

The primary industry of Torrent Pharmaceuticals Ltd is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Torrent Pharmaceuticals Ltd is listed on both BSE (code: 500420) and NSE (symbol: TORNTPHARM).

Torrent Pharmaceuticals Ltd can be reached at the registered office: Avirat, Thaltej Shilaj Road Ahmedabad, Daskroi, Gujarat, India – 380059, or through the website torrentpharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available